Reshaping the HIV treatment and prevention landscape

New commitments to growth 2021-26 2031 More than 5% sales CAGR More than 10% adjusted OP CAGR More than £33 billion sales ambition With metrics and incentives strongly aligned to shareholder value creation All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. See basis of preparation and assumptions in Appendix. CAGR is for the 5 years to 2026, using 2021 as the base year. Pipeline sales are risk-adjusted and include anticipated sales of new products and Life Cycle Innovation (LCI) launched from 2021 onwards. Note: COVID therapeutic and vaccine solutions are excluded from the above. gsk 13

View entire presentation